Effects of Aging and Inflammation on Intracellular Nucleoside Reverse Transcriptase Inhibitor Pharmacology in the WIHS Cohort
WIHS 队列中衰老和炎症对细胞内核苷逆转录酶抑制剂药理学的影响
基本信息
- 批准号:9791318
- 负责人:
- 金额:$ 13.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-09-30 至 2021-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAffectAgeAge-YearsAgingAnti-Retroviral AgentsBiological MarkersC-reactive proteinCD28 geneCD4 Lymphocyte CountCD4/CD8 ratio procedureCD8-Positive T-LymphocytesCell AgingCellsClinicalClinical DataCohort StudiesComplexDataDatabasesDetectionDiphosphatesDrug toxicityDrug usageEnrollmentFormulationGlomerular Filtration RateGoalsHIVHepatitis CHigh Risk WomanHumanImmunologic FactorsImmunologicsIn VitroInflammationInterleukin-6InterventionInvestigationKidneyMacrophage ActivationMeasuresMenopauseModelingModernizationMorbidity - disease rateNucleosidesNucleotidesOutcomeOvarianPatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacologyPlasmaPopulationProspective StudiesRegimenRenal functionResearchReverse Transcriptase InhibitorsRiskSafetySamplingStatistical ModelsT-LymphocyteTenofovirTestingTimeToxic effectVertebral columnVisitWomanWomen’s Interagency HIV StudyWorkage effectage relatedantiretroviral therapycase controldesignemtricitabineexperienceimprovedkidney dysfunctionmenmonocytemullerian-inhibiting hormoneolder womenoncologypharmacodynamic modelpharmacokinetic modelpredictive markerprospectiverepositorysenescenceurinary
项目摘要
PROJECT ABSTRACT
This application proposes to determine if age drives changes in intracellular pharmacology, and identify clinical
and immunologic factors that affect the age-pharmacology relationship by testing the hypothesis that increased
cellular activation and inflammation that occurs with aging will decrease intracellular nucleos(t)ide reverse
transcriptase inhibitor (NRTI) intracellular metabolite (IM) and endogenous nucleotide (EN) concentrations in
HIV-infected women, resulting in a decreased IM:EN ratio.
We aim to: (1) quantify and compare intracellular IM and EN concentrations in older (current age ≥60 years)
vs. younger (current age ≤5 years) HIV-infected women receiving tenofovir (TFV) and emtricitabine (FTC)
enrolled in the WIHS, as well as compare intracellular IM and EN concentrations longitudinally in older (current
age ≥60 years) vs. younger (current age ≤45years) on the same regimen; (2) determine if IL-6 and sCD163
concentrations in plasma and/or the presence of senescent cells are associated with changes in the IM:EN
ratio; and (3) quantify and compare intracellular IM and EN concentrations in HIV-infected women enrolled in
the Women's Interagency HIV Study receiving tenofovir concurrently with previously measured urinary
biomarkers, and compare IM and EN concentrations in age- and regimen-matched women who experienced
toxicity vs. those who did not.
The proposed study will build off the previous pharmacology and drug-related toxicity research conducted in
the WIHS, address questions about the pharmacology of aging in women, and provide preliminary data for
R01-level prospective investigations into the mechanism and clinical ramifications of altered IM:EN ratios in
treated HIV-infected women and men.
项目摘要
这项应用建议确定年龄是否推动细胞内药理学的变化,并确定临床
以及通过检验增加的假说来影响年龄-药理学关系的免疫因素
随着衰老发生的细胞活化和炎症会反过来减少细胞内的核(T)
转录酶抑制物(NRTI)、胞内代谢物(IM)和内源核苷酸(EN)浓度
感染艾滋病毒的妇女,导致IM:EN比率降低。
我们的目标是:(1)量化和比较老年人(当前年龄≥60岁)细胞内IM和EN浓度
接受替诺福韦(替诺福韦)和恩曲他滨(≤)治疗的年轻(当前年龄5岁)艾滋病毒感染妇女
登记参加WIHS,以及纵向比较老年人细胞内IM和EN浓度(当前
年龄≥60岁)与年轻人(当前年龄≤45岁)采用相同的方案;(2)确定IL-6和sCD163
血浆浓度和/或衰老细胞的存在与IM:EN的变化有关
比率;以及(3)量化和比较登记的HIV感染妇女的细胞内IM和EN浓度
女性机构间HIV研究同时接受替诺福韦和先前测量的尿液
生物标志物,并比较年龄和方案匹配的女性的IM和EN浓度
毒性VS那些没有毒性的人。
拟议的研究将建立在以前进行的药理学和药物相关毒性研究的基础上。
WIHS,解决有关女性衰老的药理学问题,并提供以下初步数据
R01水平的前瞻性研究,探讨IM:EN比率改变的机制和临床影响
治疗感染艾滋病毒的妇女和男子。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Julie Brumer Dumond其他文献
Julie Brumer Dumond的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Julie Brumer Dumond', 18)}}的其他基金
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
- 批准号:
10390354 - 财政年份:2021
- 资助金额:
$ 13.67万 - 项目类别:
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
- 批准号:
10600858 - 财政年份:2021
- 资助金额:
$ 13.67万 - 项目类别:
Quantifying Sex-and-Age-Related Differences in Antiretroviral Exposure and Adverse Effects in the MACS/WIHS Combined Cohort Study
MACS/WIHS 联合队列研究中抗逆转录病毒药物暴露和不良反应的性别和年龄相关差异的量化
- 批准号:
10161378 - 财政年份:2021
- 资助金额:
$ 13.67万 - 项目类别:
Physiologically-Based Pharmacokinetic Modeling to Guide Drug Dosing in Children with Obesity
基于生理学的药代动力学模型指导肥胖儿童的药物剂量
- 批准号:
10456301 - 财政年份:2018
- 资助金额:
$ 13.67万 - 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:
8231979 - 财政年份:2011
- 资助金额:
$ 13.67万 - 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:
8814163 - 财政年份:2011
- 资助金额:
$ 13.67万 - 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:
8140850 - 财政年份:2011
- 资助金额:
$ 13.67万 - 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:
8607112 - 财政年份:2011
- 资助金额:
$ 13.67万 - 项目类别:
Optimizing Antiretroviral Use in Aging: Pharmacokinetics, Response, and Toxicity
优化抗逆转录病毒药物在衰老过程中的应用:药代动力学、反应和毒性
- 批准号:
8429489 - 财政年份:2011
- 资助金额:
$ 13.67万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 13.67万 - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
$ 13.67万 - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
$ 13.67万 - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
$ 13.67万 - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
$ 13.67万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 13.67万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 13.67万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 13.67万 - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
$ 13.67万 - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
$ 13.67万 - 项目类别:
Miscellaneous Programs